donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MYGN Myriad Genetics > Key Indicators
MYGN Myriad Genetics
27.120
-0.340-1.24%
Post Mkt Price
27.12000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- 39.2266 -- 45.1691 -35.57% 40.6672 -- 40.6672
Receivable Turnover(T)
-- 6.5718 -- 6.9704 20.82% 7.6394 -- 7.6394
Inventory Turnover(T)
-- 11.5589 -- 9.7164 51.51% 9.3208 -- 9.3208
Fixed Assets Turnover(T)
-- 5.0644 -- 6.1868 -23.19% 6.1196 -- 6.1196
Total Asset Rate(T)
-- 0.5231 -- 0.5265 17.14% 0.5042 -- 0.5042
ROIC
-- -1.508% -- -0.550% 86.41% -2.053% -- -2.053%
ROE
-- -1.903% -- -0.898% 85.2% -2.942% -- -2.942%
ROA
-- -1.369% -- -0.633% 85.23% -1.986% -- -1.986%
FCF to Sales
-- -- -- -- -99.63% 0.029% -- 0.029%
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
-- 71.545% -- 71.380% 0.75% 71.387% -- 71.387%
Operating Margin
-- -23.159% -- -23.124% -29.44% -27.324% -- -27.324%
Net Margin
-- -2.618% -- -1.202% 87.39% -3.939% -- -3.939%
EBITDA Margin
-- 0.0126% -- 0.041% 108.1% 0.0178% -- 0.0178%
R & D Expense Ratio
-- 12.020% -- 11.720% -1.9% 11.860% -- 11.860%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 86.850% -- 86.850%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-0.77% 9.225% -65.35% 8.052% -73.25% 8.194% -- 8.194%
Total Assets to Common Equity
-15.25% 127.739% -13.5% 132.134% -10.79% 136.464% -- 136.464%
Debt to Asset Ratio
-52.2% 10.629% -61.91% 9.462% -70.3% 9.537% -- 9.537%
Current Ratio
54.22% 3.0668 16.53% 2.5747 5.16% 2.373 -- 2.373
Quick Ratio
175.05% 2.6307 21.86% 2.2295 7.41% 2.1101 -- 2.1101
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- 48.41% -3.149% -- --
Revenue CAGR(5Y)
-- -- -- -- 35.73% -1.578% -- --
FCF 1 Year Growth
-- -- -- -- -197.57% -97.471% -- --
FCF CAGR(3Y)
-- -- -- -- -308.72% -83.350% -- --
FCF CAGR(5Y)
-- -- -- -- -356.45% -70.339% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
CEO: Diaz, Paul J.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...